Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transparency in Action: FDA Comments on Pirfenidone

This article was originally published in RPM Report

Executive Summary

While FDA's proposed transparency initiative is still under discussion, there are signs that the agency is already taking a more liberal view of its disclosure polices. InterMune's pirfenidone is a case in point.

You may also be interested in...



FDA Releases Report on Transparency to Regulated Industry: Not Much To See Here

The third phase of the Food & Drug Administration’s Transparency Initiative lists 19 ways that the agency plans to improve transparency to the industries it regulates. FDA is also seeking comments on five proposed steps. Unlike earlier phases, there isn’t too much to see here.

Open Season at Open Sessions: Benlysta May Presage Resurgence of Public Pressure on FDA Committees

FDA would be wise to prepare for a new round of active, emotive open public sessions after the impact of the public testimony at the Benlysta lupus drug review on November 16. It’s been a long-time since a public session has had such a direct impact on creating a pro-approval atmosphere at a committee meeting.

Transparency in Action: FDA Comments on Pirfenidone

While FDA's proposed transparency initiative is still under discussion, there are signs that the agency is already taking a more liberal view of its disclosure polices. InterMune's pirfenidone is a case in point.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel